S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:CERT

Certara (CERT) Stock Forecast, Price & News

$14.08
-0.33 (-2.29%)
(As of 04:00 PM ET)
Compare
Today's Range
$14.07
$14.83
50-Day Range
$13.98
$19.58
52-Week Range
$10.60
$24.96
Volume
482,132 shs
Average Volume
1.11 million shs
Market Capitalization
$2.25 billion
P/E Ratio
117.34
Dividend Yield
N/A
Price Target
$20.86

Certara MarketRank™ Forecast

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
47.0% Upside
$20.86 Price Target
Short Interest
Healthy
6.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.48mentions of Certara in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$747,870 Sold Last Quarter
Proj. Earnings Growth
-3.03%
From $0.33 to $0.32 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

63rd out of 968 stocks

Prepackaged Software Industry

14th out of 199 stocks


CERT stock logo

About Certara (NASDAQ:CERT) Stock

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

CERT Price History

CERT Stock News Headlines

Robert W. Baird Reaffirms Their Hold Rating on Certara (CERT)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Certara Inc.
What Is Certara, Inc.'s (NASDAQ:CERT) Share Price Doing?
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Berenberg Bank Keeps Their Buy Rating on Certara (CERT)
Jefferies Downgrades Certara (CERT)
Jefferies downgrades Certara (CERT) to a Hold
Barclays Sticks to Its Hold Rating for Certara (CERT)
The Latest Analyst Ratings for Certara
Berenberg Bank Sticks to Its Buy Rating for AbSci (ABSI)
Q2 2023 Certara Inc Earnings Call
Certara Reports Second Quarter 2023 Financial Results
See More Headlines
Receive CERT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Certara and its competitors with MarketBeat's FREE daily newsletter.

CERT Company Calendar

Last Earnings
8/09/2023
Today
9/22/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CERT
Fax
N/A
Employees
1,204
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.86
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+45.7%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

Net Income
$14.73 million
Pretax Margin
6.55%

Debt

Sales & Book Value

Annual Sales
$335.64 million
Cash Flow
$0.65 per share
Book Value
$6.76 per share

Miscellaneous

Free Float
155,622,000
Market Cap
$2.29 billion
Optionable
Not Optionable
Beta
1.46
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. William F. Feehery Ph.D. (Age 52)
    CEO & Director
    Comp: $1.35M
  • Mr. Leif E. Pedersen (Age 58)
    Pres & Chief Commercial Officer
    Comp: $625.53k
  • Dr. Robert P. Aspbury Ph.D. (Age 51)
    Pres of Certara Scientific Software
    Comp: $518.09k
  • Dr. Patrick F. Smith Pharm.D. (Age 52)
    Pres of Drug Devel. Solutions
    Comp: $621.58k
  • Mr. John E. Gallagher III (Age 50)
    Chief Financial Officer
  • Mr. Max Kanevsky
    Chief Technology Officer
  • Prof. Amin Rostami PharmD
    Ph.D., FCP, Chief Scientific Officer
  • Mr. Richard M. TraynorMr. Richard M. Traynor (Age 51)
    Sr. VP, Gen. Counsel & Sec.
  • Mr. Ron DiSantis
    Sr. VP of Corp. Devel.
  • Ms. Sheila Rocchio MBA
    Chief Marketing Officer













CERT Stock - Frequently Asked Questions

Should I buy or sell Certara stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Certara in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CERT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERT, but not buy additional shares or sell existing shares.
View CERT analyst ratings
or view top-rated stocks.

What is Certara's stock price forecast for 2023?

8 analysts have issued 1-year target prices for Certara's stock. Their CERT share price forecasts range from $16.00 to $28.00. On average, they expect the company's share price to reach $20.86 in the next twelve months. This suggests a possible upside of 45.7% from the stock's current price.
View analysts price targets for CERT
or view top-rated stocks among Wall Street analysts.

How have CERT shares performed in 2023?

Certara's stock was trading at $16.07 at the beginning of 2023. Since then, CERT shares have decreased by 10.9% and is now trading at $14.32.
View the best growth stocks for 2023 here
.

Are investors shorting Certara?

Certara saw a decline in short interest in August. As of August 31st, there was short interest totaling 6,520,000 shares, a decline of 5.5% from the August 15th total of 6,900,000 shares. Based on an average daily volume of 895,600 shares, the days-to-cover ratio is currently 7.3 days. Currently, 6.0% of the shares of the company are short sold.
View Certara's Short Interest
.

When is Certara's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our CERT earnings forecast
.

How were Certara's earnings last quarter?

Certara, Inc. (NASDAQ:CERT) announced its earnings results on Wednesday, August, 9th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.08 by $0.02. The business had revenue of $90.45 million for the quarter, compared to analyst estimates of $92.04 million. Certara had a trailing twelve-month return on equity of 5.56% and a net margin of 5.45%.

What guidance has Certara issued on next quarter's earnings?

Certara issued an update on its FY23 earnings guidance on Wednesday, August, 9th. The company provided EPS guidance of $0.44-$0.48 for the period, compared to the consensus earnings per share estimate of $0.52. The company issued revenue guidance of $345-$360 million, compared to the consensus revenue estimate of $376.55 million.

When did Certara IPO?

(CERT) raised $500 million in an initial public offering on Friday, December 11th 2020. The company issued 24,400,000 shares at $19.00-$22.00 per share. Jefferies, Morgan Stanley, BofA Securities, Credit Suisse, Barclays and William Blair acted as the underwriters for the IPO.

What is Certara's stock symbol?

Certara trades on the NASDAQ under the ticker symbol "CERT."

Who are Certara's major shareholders?

Certara's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.07%), Baillie Gifford & Co. (5.88%), William Blair Investment Management LLC (4.43%), Clearbridge Investments LLC (2.60%), ArrowMark Colorado Holdings LLC (2.57%) and JPMorgan Chase & Co. (2.38%). Insiders that own company stock include Avatar Parent LP Eqt, Craig R Rayner, Eran Broshy, James E Cashman III, Jieun W Choe, Justin Edge, Leif E Pedersen, Mason P Slaine, Matthew M Walsh, Michael Andrew Schemick, Patrick F Smith, Richard M Traynor, Robert Aspbury, Stephen M Mclean and William F Feehery.
View institutional ownership trends
.

How do I buy shares of Certara?

Shares of CERT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Certara's stock price today?

One share of CERT stock can currently be purchased for approximately $14.32.

How much money does Certara make?

Certara (NASDAQ:CERT) has a market capitalization of $2.29 billion and generates $335.64 million in revenue each year. The company earns $14.73 million in net income (profit) each year or $0.12 on an earnings per share basis.

How many employees does Certara have?

The company employs 1,204 workers across the globe.

How can I contact Certara?

Certara's mailing address is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. The official website for the company is www.certara.com. The company can be reached via phone at 609-716-7900 or via email at ir@certara.com.

This page (NASDAQ:CERT) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -